Clinical Trial Update: A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Dara-CyBorD in previously untreated and relapsed multiple myeloma completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dara-CyBorD (daratumumab + cyclophosphamide + bortezomib + dexamethasone)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-04-03